Decreased annexin I expression in prostatic adenocarcinoma and in high-grade prostatic intraepithelial neoplasia

Histopathology

Volumn 47, Issue 6, 2005, Pages 597-601

  Patton, K T ^a   Chen, H M ^b   Joseph, L ^b   Yang, Ximing J ^a,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c NORTHWESTERN MEMORIAL HOSPITAL   (United States)

Author keywords

Annexin I; PIN; Prostate adenocarcinoma

Indexed keywords

LIPOCORTIN 1;

ARTICLE; BENIGN TUMOR; CANCER GRADING; CANCER GROWTH; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN BINDING; PROTEIN EXPRESSION;

ADENOCARCINOMA; ANNEXIN A1; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 28844443606     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2005.02300.x     Document Type: Article

References (18)

1. Stewart SL, King JB, Thompson TD et al. Cancer mortality surveillance-United States, 1990-2000. MMWR Surveill. Summ. 2004; 53; 1-108.
2. Srivastava M, Bubendorf L, Srikantan V et al. ANX7, a candidate tumor suppressor gene for prostate cancer. Proc. Natl Acad. Sci. USA 2001; 98; 4575-4580.
3. Chetcuti A, Margan SH, Russell P et al. Loss of annexin II heavy and light chains in prostate cancer and its precursors. Cancer Res. 2001; 61; 6331-6334.
4. Schwartz-Albiez R, Koretz K, Moller P et al. Differential expression of annexins I and II in normal and malignant human mammary epithelial cells. Differentiation 1993; 52; 229-237.
5. Liu JW, Shen JJ, Tanzillo-Swarts A et al. Annexin II expression is reduced or lost in prostate cancer cells and its re-expression inhibits prostate cancer cell migration. Oncogene 2003; 22; 1475-1485.
6. Liu J, Rothermund CA, Ayala-Sanmartin J et al. Nuclear annexin II negatively regulates growth of LNCaP cells and substitution of Series 11 and 25 to glu prevents nucleo-cytoplasmic shuttling of annexin II. BMC Biochem. 2003; 4; 10.
7. Xin W, Rhodes DR, Ingold C et al. Dysregulation of the annexin family protein family is associated with prostate cancer progression. Am. J. Pathol. 2003; 162; 255-261.
8. Kang JS, Calvo BF, Maygarden SJ et al. Dysregulation of annexin I protein expression in high-grade prostatic intraepithelial neoplasia and prostate cancer. Clin. Cancer Res. 2002; 8; 117-123.
9. Rand JH. The annexinopathies: a new category of diseases. Biochim. Biophys. Acta 2000; 1498; 169-173.
10. Rothhut B. Participation of annexins in protein phosphorylation. Cell Mol. Life Sci. 1997; 53; 522-526.
11. Alldridge LC, Bryant CE. Annexin 1 regulates cell proliferation by disruption of cell morphology and inhibition of cyclin D1 expression through sustained activation of the ERK1/2 MAPK signal. Exp. Cell Res. 2003; 290; 93-107.
12. Kim SW, Rhee HJ, Ko J et al. Inhibition of cytosolic phospholipase A2 by annexin I. Specific interaction model and mapping of the interaction site. J. Biol. Chem. 2001; 276; 15712-15719.
13. Flower RJ, Rothwell NJ. Lipocortin-1: cellular mechanisms and clinical relevance. Trends Pharmacol. Sci. 1994; 15; 71-76.
14. Paweletz CP, Ornstein DK, Roth MJ et al. Loss of annexin 1 correlates with early onset of tumorigenesis in esophageal and prostate carcinoma. Cancer Res. 2000; 60; 6293-6297.
15. Bostwick DG, Brawer MK. Prostatic intra-epithelial neoplasia and early invasion in prostate cancer. Cancer 1987; 59; 788-794.
16. Vaarala MH, Porvari K, Kyllonen A et al. Differentially expressed genes in two LNCaP prostate cancer cell lines reflecting changes during prostate cancer progression. Lab. Invest. 2000; 80; 1259-1268.
17. Smitherman AB, Mohler JL, Maygarden SJ et al. Expression of annexin I, II and VII proteins in androgen stimulated and recurrent prostate cancer. J. Urol. 2004; 171; 916-920.
18. Kim HL, Vander Griend DJ, Yang X et al. Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers. Cancer Res. 2001; 61; 2833-2837.